Search for other papers by Bliss Anderson in
Google Scholar
PubMed
Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed
Introduction Immunotherapy with immune checkpoint inhibitors (CPI’s) has been revolutionising the management of advanced malignancies with their success in improving overall patient survival ( 1 , 2 ). CPI’s are antibodies that block T
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Nikolaos Kyriakakis in
Google Scholar
PubMed
Search for other papers by Marilena Giannoudi in
Google Scholar
PubMed
Search for other papers by Satish S Kumar in
Google Scholar
PubMed
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Khyatisha Seejore in
Google Scholar
PubMed
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Harpal Randeva in
Google Scholar
PubMed
Leeds Institute of Medical Research, University of Leeds, UK
Search for other papers by Adam Glaser in
Google Scholar
PubMed
Search for other papers by Michelle Kwok-Williams in
Google Scholar
PubMed
Search for other papers by Georgina Gerrard in
Google Scholar
PubMed
Search for other papers by Carmel Loughrey in
Google Scholar
PubMed
Search for other papers by Ahmed Al-Qaissi in
Google Scholar
PubMed
Search for other papers by Ramzi Ajjan in
Google Scholar
PubMed
Search for other papers by Julie Lynch in
Google Scholar
PubMed
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Robert D Murray in
Google Scholar
PubMed
Introduction Malignant brain tumours affect both children and adults, although have markedly different long-term outcomes. Five-year survival rates of 73% have been reported following multi-modality treatment in children diagnosed with
PhD School of Clinical and Experimental Biomedical Sciences, University of Messina, Messina, Sicily, Italy
Search for other papers by G Giuffrida in
Google Scholar
PubMed
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy
Search for other papers by F Ferraù in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by R Laudicella in
Google Scholar
PubMed
Search for other papers by O R Cotta in
Google Scholar
PubMed
Search for other papers by E Messina in
Google Scholar
PubMed
Neuroradiology Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Search for other papers by F Granata in
Google Scholar
PubMed
Neurosurgery Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Search for other papers by F F Angileri in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by A Vento in
Google Scholar
PubMed
Search for other papers by A Alibrandi in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by S Baldari in
Google Scholar
PubMed
PhD School of Clinical and Experimental Biomedical Sciences, University of Messina, Messina, Sicily, Italy
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy
Search for other papers by S Cannavò in
Google Scholar
PubMed
patients have been summarized in the study by Priola et al . ( 6 ). GBq, giga becquerel; NA, not available; PFS, progression-free survival (from PRRT); RT, radiotherapy; TMZ, temozolomide. Overall evaluation On the basis of our
Search for other papers by Yukari Maki in
Google Scholar
PubMed
Search for other papers by Kiyomi Horiuchi in
Google Scholar
PubMed
Search for other papers by Takahiro Okamoto in
Google Scholar
PubMed
burden poses paramount importance for society and individuals. Most patients with PTC have a good prognosis, whereas a few may experience recurrence or even death ( 4 , 5 ). In addition to the oncologic events, subjective sequelae following diagnosis and
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Search for other papers by Marra Jai Aghajani in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
South West Sydney Clinical School, UNSW Sydney, Sydney, Australia
Search for other papers by Tara Laurine Roberts in
Google Scholar
PubMed
Saint Vincent’s Clinical School, UNSW Sydney, Sydney, Australia
SydPath, Saint Vincent’s Hospital, Sydney, Australia
Search for other papers by Tao Yang in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Search for other papers by Charles Eugenio McCafferty in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Centre for Oncology Education and Research Translation (CONCERT), Liverpool, New South Wales, Australia
Search for other papers by Nicole J Caixeiro in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
South West Sydney Clinical School, UNSW Sydney, Sydney, Australia
Search for other papers by Paul DeSouza in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Department of Head & Neck Surgery, Liverpool Hospital, Liverpool, New South Wales, Australia
Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia
Search for other papers by Navin Niles in
Google Scholar
PubMed
/niceopdivoappraisal.pdf ) 14 Wang L Wang H Chen H Wang WD Chen XQ Geng QR Xia ZJ Lu Y . Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma . Oncotarget 2015 6 . ( https
Search for other papers by Renea A Taylor in
Google Scholar
PubMed
Search for other papers by Jennifer Lo in
Google Scholar
PubMed
Search for other papers by Natasha Ascui in
Google Scholar
PubMed
Search for other papers by Matthew J Watt in
Google Scholar
PubMed
, although the slow growing nature of prostate cancer means it often takes decades for this progression to become clinically relevant (3) . Being a slow growing cancer, the 5-year survival rate from prostate cancer is a very high (∼98.9% based on SEER 2005
Search for other papers by Kunal Thakkar in
Google Scholar
PubMed
Search for other papers by Swati Ramteke-Jadhav in
Google Scholar
PubMed
Search for other papers by Rajeev Kasaliwal in
Google Scholar
PubMed
Search for other papers by Saba Samad Memon in
Google Scholar
PubMed
Search for other papers by Virendra Patil in
Google Scholar
PubMed
Search for other papers by Puja Thadani in
Google Scholar
PubMed
Search for other papers by Nilesh Lomte in
Google Scholar
PubMed
Search for other papers by Shilpa Sankhe in
Google Scholar
PubMed
Search for other papers by Atul Goel in
Google Scholar
PubMed
Search for other papers by Sridhar Epari in
Google Scholar
PubMed
Search for other papers by Naina Goel in
Google Scholar
PubMed
Search for other papers by Anurag Lila in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
, was the most common complication seen in their series, while mean duration of disease free survival was 28 months on long-term follow-up. At 10 months of follow-up, our patient remains on hormone replacement therapy with no tumor residue. MPNST
Search for other papers by Elizaveta Mamedova in
Google Scholar
PubMed
Search for other papers by Natalya Mokrysheva in
Google Scholar
PubMed
Search for other papers by Evgeny Vasilyev in
Google Scholar
PubMed
Search for other papers by Vasily Petrov in
Google Scholar
PubMed
Search for other papers by Ekaterina Pigarova in
Google Scholar
PubMed
Search for other papers by Sergey Kuznetsov in
Google Scholar
PubMed
Search for other papers by Nikolay Kuznetsov in
Google Scholar
PubMed
Search for other papers by Liudmila Rozhinskaya in
Google Scholar
PubMed
Institute of Clinical Endocrinology, Endocrinology Research Center, Moscow, Russian Federation
Search for other papers by Galina Melnichenko in
Google Scholar
PubMed
Search for other papers by Ivan Dedov in
Google Scholar
PubMed
Search for other papers by Anatoly Tiulpakov in
Google Scholar
PubMed
the abovementioned genes were as follows: NM_130799.2, NM_000388.3, NM_024529.4, NM_078467.2, NM_004064.4, NM_000076.2, NM_000077.4, NM_001262.2, NM_001800, respectively. ANNOVAR free software ( http://annovar.openbioinformatics.org ) was used for
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
Endocrine, Cardiovascular & Metabolic Research, Department of Anatomy, Multidisciplinary Unit for Biomedical Research (UMIB), Instituto de Ciências Biomédicas Abel Salazar, University of Porto (ICBAS/UP), Porto, Portugal
Search for other papers by Sofia S Pereira in
Google Scholar
PubMed
Search for other papers by Mariana P Monteiro in
Google Scholar
PubMed
Search for other papers by Sonir R Antonini in
Google Scholar
PubMed
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
Department of Endocrinology, Hospital S. João, Porto, Portugal
Search for other papers by Duarte Pignatelli in
Google Scholar
PubMed
found to be different in malignant when compared to benign ACT ( 24 ). Concerning prognostic differences in children with ACC, a low CASP3 expression was found to be associated with a lower 5-year event-free survival, while low levels of CASP9 were
Search for other papers by Anello Marcello Poma in
Google Scholar
PubMed
Search for other papers by Riccardo Giannini in
Google Scholar
PubMed
Search for other papers by Paolo Piaggi in
Google Scholar
PubMed
Search for other papers by Clara Ugolini in
Google Scholar
PubMed
Search for other papers by Gabriele Materazzi in
Google Scholar
PubMed
Search for other papers by Paolo Miccoli in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Fulvio Basolo in
Google Scholar
PubMed
FTC diagnosis in the presence of capsular invasion (even partial) without vascular involvement, since these tumors, although rarely, can develop recurrences and metastatic disease ( 14 , 15 ). Despite the unresolved issues in MI-FTC diagnosis, it has